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Fibroblast growth factor-21 (FGF21) is a circulating
hepatokine that beneficially affects carbohydrate
and lipid metabolism. Here, we report that FGF21
is also an inducible, fed-state autocrine factor in
adipose tissue that functions in a feed-forward loop
to regulate the activity of peroxisome proliferator-
activated receptor g (PPARg), a master transcrip-
tional regulator of adipogenesis. FGF21 knockout
(KO) mice display defects in PPARg signaling
including decreased body fat and attenuation of
PPARg-dependent gene expression. Moreover,
FGF21-KO mice are refractory to both the beneficial
insulin-sensitizing effects and the detrimental weight
gain and edema side effects of the PPARg agonist
rosiglitazone. This loss of function in FGF21-KO
mice is coincident with a marked increase in the
sumoylation of PPARg, which reduces its transcrip-
tional activity. Adding back FGF21 prevents sumoy-
lation and restores PPARg activity. Collectively,
these results reveal FGF21 as a key mediator of the
physiologic and pharmacologic actions of PPARg.INTRODUCTION
Although white adipose tissue (WAT) serves as a repository for
fatty acids, it also plays a crucial role in regulating overall energy
homeostasis (Spiegelman and Flier, 2001). Either too little or
too much WAT contributes to metabolic abnormalities that
include hyperlipidemia, insulin resistance, and type 2 diabetes.
Thus, maintaining the appropriate amount of WAT is crucial for
optimal health.556 Cell 148, 556–567, February 3, 2012 ª2012 Elsevier Inc.Peroxisome proliferator-activated receptor g (PPARg) is
a member of the nuclear receptor family of ligand-activated
transcription factors that is highly expressed in WAT (Chawla
et al., 1994; Tontonoz et al., 1994a), where it is required for
adipocyte differentiation (Rosen et al., 1999; Tontonoz et al.,
1994b). PPARg exists as two isoforms, PPARg1 and PPARg2,
with PPARg2 containing an additional 30 amino acids at its amino
terminus (Tontonoz et al., 1994a). PPARg cooperates with the
CCAAT/enhancer-binding protein (C/EBP) family of transcription
factors to regulate adipogenesis. C/EBPb and C/EBPd are
present early during adipogenesis and inducePPARg expression
(Cao et al., 1991; Wu et al., 1995, 1996, 1999; Yeh et al., 1995).
C/EBPa is expressed later and together with PPARg governs
the adipocyte-specific pattern of gene expression (Lefterova
et al., 2008; Tontonoz et al., 1994b; Wu et al., 1998). Although
the identity of the endogenous PPARg ligand is unknown, PPARg
is activated by various fatty acids and fatty acid metabolites as
well as by the thiazolidinedione (TZD) class of insulin-sensitizing
drugs, which include rosiglitazone and pioglitazone (Tontonoz
and Spiegelman, 2008; Willson et al., 2001). PPARg activity is
also regulated by posttranslational modification, including
phosphorylation and sumoylation. Phosphorylation of PPARg2
at S112 by MAP kinases represses its transcriptional activity
by inhibiting ligand binding and altering cofactor recruitment
(Adams et al., 1997; Hu et al., 1996; Shao et al., 1998). Phosphor-
ylation of PPARg2 at S273 by CDK5 does not alter its adipogenic
capacity but dysregulates numerous genes involved in obesity
(Choi et al., 2010). Sumoylation of PPARg2 at K107 blocks its
transcriptional activity (Floyd and Stephens, 2004; Ohshima
et al., 2004; Yamashita et al., 2004), possibly by promoting
corepressor recruitment. In macrophages, sumoylation of
PPARg2 at K395 results in its recruitment to the promoters of
inflammatory genes, where it inhibits transcription by preventing
clearance of corepressor complexes (Pascual et al., 2005).
Fibroblast growth factor-21 (FGF21) is an atypical member
of the FGF family that functions as a hormone to regulate
carbohydrate and lipid metabolism. FGF21 was first shown to
regulate metabolism in 3T3-L1 adipocytes, where it stimulated
glucose uptake (Kharitonenkov et al., 2005). When administered
pharmacologically to obese, insulin-resistant rodents and
monkeys, FGF21 increased energy expenditure, insulin sensi-
tivity, and weight loss, and normalized carbohydrate and lipid
parameters (Berglund et al., 2009; Coskun et al., 2008; Kharito-
nenkov et al., 2005, 2007; Xu et al., 2009). FGF21 is strongly
induced in liver in response to fasting or ketogenic diet (Badman
et al., 2007; Inagaki et al., 2007; Lunda˚sen et al., 2007). Consis-
tent with a role in the adaptive fasting response, FGF21 stimu-
lated hepatic ketogenesis and gluconeogenesis in lean mice
(Potthoff et al., 2009), and FGF21-transgenic mice were growth
inhibited and sensitized to the hibernation-like state of torpor
(Inagaki et al., 2007, 2008). Mechanistically, FGF21 activates
cell signaling by binding to a heteromeric cell-surface receptor
tyrosine kinase complex composed of b-Klotho and a conven-
tional FGF receptor (FGFR), with FGFR1c being the preferred
isoform for FGF21 (Ogawa et al., 2007; Suzuki et al., 2008).
Both b-Klotho and FGFR1c are abundantly expressed in WAT
(Fon Tacer et al., 2010; Kurosu et al., 2007), where FGF21-
regulated genes are involved in a variety of metabolic processes
including lipogenesis, lipolysis, and fatty acid oxidation (Coskun
et al., 2008; Xu et al., 2009). Based upon these findings, it was
proposed that FGF21 induces futile cycling and energy expendi-
ture in WAT (Coskun et al., 2008).
During fasting, FGF21 expression in liver is controlled by
PPARa, and pharmacologic administration of PPARa agonists
(e.g., the fibrate class of hypolipidemic drugs) induces hepatic
expression of FGF21 (Badman et al., 2007; Inagaki et al., 2007;
Lunda˚sen et al., 2007). However, FGF21 is also induced by
PPARg agonists, including TZDs, in WAT and isolated adipo-
cytes (Muise et al., 2008; Wang et al., 2008; Zhang et al.,
2008). Although FGF21 and rosiglitazone were shown to coop-
erate in promoting differentiation and glucose uptake in 3T3-L1
adipocytes (Moyers et al., 2007), to our knowledge, the func-
tional relationship between TZDs and FGF21 has not been
explored in vivo. Here, we show that FGF21 acts in an autocrine
fashion in WAT to regulate PPARg activity, to enhance adipo-
genesis, and to contribute to both the therapeutic and side
effects of TZDs. These studies reveal a previously unrecognized
facet of FGF21 biology.
RESULTS
FGF21 Is Induced in WAT by Feeding
A previous study showed that Fgf21 is induced by rosiglitazone
in WAT of wild-type (WT) and db/db mice (Muise et al., 2008).
Consistent with these findings, FGF21 mRNA and protein
levels were induced by rosiglitazone in WAT but not liver of
WT mice (Figures 1A–1D). Conversely, FGF21 mRNA and
protein concentrations were increased by the PPARa agonist,
GW7647, in liver but not WAT (Figures 1A–1D). Notably,
whereas GW7647 markedly increased plasma FGF21 concen-
trations, rosiglitazone had no effect (Figure 1E). In experiments
performed with isolated adipocytes, rosiglitazone but not
GW7647 increased both FGF21 mRNA levels and protein
concentrations in the media (Figure S1 available online). Takentogether, these data suggest that FGF21 is secreted from WAT
but acts locally in an autocrine or paracrine fashion instead of
entering the circulation.
To determine whether Fgf21 is induced in WAT by diet, Fgf21
mRNA levels were measured at 4 hr intervals in WAT and liver
from mice restricted to feeding during a 4 hr period in the
middle of the dark cycle. As expected, Fgf21 expression was
highest in liver just prior to feeding (Figure 1F). In contrast,
Fgf21 expression in WAT was very low during fasting but
spiked 4 hr after feeding to an absolute level comparable to
that seen in liver of fasted mice (Figure 1F). Thus, Fgf21 is
induced in WAT by either TZD treatment or feeding. Under
these conditions we saw no significant changes in the levels of
circulating FGF21 (data not shown), which is consistent with
increases in blood FGF21 concentrations requiring fasting for
24 hr or more (Muise et al., 2008).
FGF21-KO Mice Have Mild Lipodystrophy
Given the regulation of Fgf21 in WAT, we examined whether
FGF21 knockout (KO) mice have an adipose tissue phenotype.
Although FGF21-KO mice had no change in body mass or fluid
mass, they had a significant decrease in total fat mass and
a significant increase in lean mass (Figures 2A–2D). There
was no difference in food intake between WT and FGF21-KO
mice (data not shown). Consistent with these findings,
FGF21-KO mice had significantly reduced amounts of epidid-
ymal, subcutaneous, mesenteric, retroperitoneal, and inter-
scapular brown adipose tissue (BAT) (Figure 2E). There was
no difference in the DNA content of epididymal WAT from WT
and FGF21-KO mice (Figure 2F), indicating that the decreased
adiposity was a consequence of smaller adipocytes rather than
a decrease in adipocyte number. This difference in adipocyte
size was confirmed by histomorphometry (Figures 2G and
2H). Similar effects on fat mass, lean mass, and epididymal,
subcutaneous, and retroperitoneal adipose depot mass were
seen in FGF21-KO mice crossed into the C57Bl/6 background
(Figures S2A–S2E). We note that two other groups reported
increased adiposity in FGF21-KO mice (Badman et al., 2009;
Hotta et al., 2009). A possible explanation for this discrepancy
is that the diets used by these groups contained soy, whereas
ours did not.
FGF21 Enhances Adipocyte Differentiation
To determine whether the adipose tissue phenotype was cell
autonomous, we examined the differentiation of preadipocytes
derived from WT and FGF21-KO mice. Fgf21 mRNA levels
were low but detectable in WT preadipocytes prior to differenti-
ation (Figure 3A). Fgf21 expression decreased during the first
day of differentiation but then rose steadily over the 8 day
differentiation protocol. The mRNA encoding b-Klotho (Klb), an
essential component of the FGF21 receptor (Ogawa et al.,
2007; Suzuki et al., 2008), was virtually undetectable until day
4 of differentiation and then rose throughout the differentiation
period (Figure 3A). Interestingly, Klb mRNA levels were lower in
FGF21-KO adipocytes but restored by inclusion of recombinant
FGF21 in the differentiation medium (Figure 3A). Expression of
Fgfr1c, which encodes the other subunit of the FGF21 receptor,
decreased during the early stages of differentiation and wasCell 148, 556–567, February 3, 2012 ª2012 Elsevier Inc. 557
Figure 1. FGF21 Is Differentially Regulated by PPARa and PPARg Agonists
(A–E) Two-month-old male C57Bl/6 mice fed regular chow were treated for 17 hr with GW7647 (10 mg/kg), rosiglitazone (Rosi; 10 mg/kg), or vehicle (1%
methylcellulose). Fgf21mRNA in epididymal (e) WAT (A) and liver (B) was measured by qRT-PCR. Ct values are indicated. FGF21 protein concentrations in eWAT
(C), liver (D), and plasma (E) were measured by ELISA. For (A)–(E), n = 4/group.
(F) Eight- to ten-week-old male C57Bl/6 mice were food entrained for 2 weeks by restricting their access to chow to a 4 hr period in the middle of the dark cycle.
Tissues were collected at 4 hr intervals over a 24 hr period, and Fgf21 mRNA was analyzed by qRT-PCR. Data were normalized to Fgf21 mRNA levels at their
lowest point (16 hr for WAT, 4 hr for liver) and are double plotted (n = 6/group).
Error bars represent the mean ± standard error of the mean (SEM) (a, p < 0.05 versus vehicle; b, p < 0.01 versus vehicle). See also Figure S1.unaffected by the absence of FGF21 (Figure 3A). These data
suggest that FGF21 signaling initiates between days 2 and 4 of
adipocyte differentiation.
We next examined the temporal pattern of expression for
a panel of genes that is expressed during the differentiation
process. The expression pattern for Cebpb and Cebpd, which
play important roles in the early stages of adipocyte differentia-
tion (Cao et al., 1991; Wu et al., 1999; Yeh et al., 1995), was
similar between WT and FGF21-KO adipocytes and unaffected
by treatment with recombinant FGF21 (Figure 3A). In contrast
the induction of Cebpa and Pparg mRNAs was delayed in
FGF21-KO adipocytes. Whereas Pparg expression was effi-
ciently restored by recombinant FGF21, Cebpa expression was
not (Figure 3A). The mRNAs encoding the fatty acid binding
protein, aP2, and the lipogenic proteins solute carrier family
25, member 1 (SLC25A1), ATP citrate lyase (ACLY), malic
enzyme (ME1), acetyl-CoA carboxylase a (ACACA), fatty acid
synthase (FASN), and diacylglycerol O-acyltransferase 2
(DGAT2) had similar expression patterns: the level of each was
reduced in FGF21-KO adipocytes and at least partially restored
by treatment with recombinant FGF21 (Figure 3A). For Cebpa,558 Cell 148, 556–567, February 3, 2012 ª2012 Elsevier Inc.Pparg, and most of the lipogenic genes, reduced expression
was first observed at day 4 of differentiation, consistent with
when Klb mRNA first appears in WT adipocytes (Figure 3A).
Phosphoenolpyruvate carboxykinase (Pck1), which was induced
only at day 8 of differentiation, was also reduced in FGF21-KO
adipocytes and partially restored by recombinant FGF21 (Fig-
ure 3A). In agreement with the lipogenic gene expression data,
lipid accumulation was reduced in FGF21-KO adipocytes and
restored to WT levels in the presence of recombinant FGF21
(Figure 3B).
FGF21 Stimulates PPARg Transcriptional Activity
The impaired differentiation and lipid accumulation in FGF21-KO
adipocytes suggested that FGF21 might regulate PPARg
activity. To examine this, WT and FGF21-KO adipocytes were
differentiated in the presence or absence of rosiglitazone. As
expected, rosiglitazone treatment increased lipogenic gene
expression and lipid accumulation in WT adipocytes (Figures
4A and 4B). However, the stimulatory effects of rosiglitazone
were attenuated in FGF21-KO adipocytes. Inclusion of recom-
binant FGF21 rescued the effect of rosiglitazone on gene
Figure 2. FGF21-KO Mice Have Decreased
Fat Mass and Adipocyte Size
(A–E) The mass of various body depots was
measured in 2-month-old male wild-type (WT) and
FGF21-KOmice fed regular chow. For (E), adipose
tissue mass was measured and normalized to
body weight for epididymal (e), subcutaneous (sc),
mesenteric (m), retroperitoneal (rp), and BAT
depots. For (A)–(D), n = 11–12/group; for (E), n = 6/
group.
(F) DNA content of eWAT pads was measured and
normalized to body mass (n = 4/group).
(G) Representative hematoxylin and eosin-stained
eWAT sections from WT and FGF21-KO mice.
Scale bars, 100 mM.
(H) Adipocyte size was measured using images
of eWAT sections and ImageJ software (n > 150
cells/group).
Error bars represent the mean ± SEM (a, p < 0.05
versus WT; b, p < 0.01 versus WT; c, p < 0.005).
See also Figure S2.expression and lipid accumulation in the FGF21-KO adipocytes
(Figures 4A and 4B).
Total PPARg protein levels were unchanged in primary
adipocytes either lacking endogenous FGF21 or treated with
recombinant FGF21 (Figure 4C). Likewise, there was no change
in the level of PPARg phosphorylated at S112 under these
conditions (Figure S3A). Notably, however, there was a signifi-
cant increase in sumoylated PPARg in FGF21-KO adipocytes
(Figure 4C). This increase in PPARg sumoylation was reversed
by including recombinant FGF21 in the media (Figure 4C). In
agreement with these in vitro results, there was a significant
increase in PPARg sumoylation in WAT from FGF21-KO mice
(Figure 4D) and a corresponding decrease in PPARg target
gene expression (Figure 4E). There was no change in PPARg
phosphorylation at either S112 or S273 in WAT from FGF21-
KO mice (Figures S3A and S3B). Similar effects on PPARg
sumoylation and target gene expression were seen in FGF21-
KO mice crossed onto the C57Bl/6 background (Figures S3C
and S3D). Taken together, the in vitro and in vivo data suggest
that FGF21 increases PPARg transcriptional activity by sup-
pressing its sumoylation.
PPARg can be sumoylated at K107 and K395 with different
transcriptional outcomes (Floyd and Stephens, 2004; OhshimaCell 148, 556–567et al., 2004; Pascual et al., 2005; Yama-
shita et al., 2004). To determine at which
position PPARg is sumoylated in FGF21-
KO adipocytes, the sumoylation sites
were mutated either singly or together
in the context of a 3xFlag-tagged
PPARg, and the tagged PPARg mutants
introduced into FGF21-KO adipocytes.
Mutating K107 (K107R) but not K395
(K395R) blocked PPARg sumoylation as
measured by immunoprecipitation with
a Flag antibody followed by western
blot analysis for the 80 kDa sumoylated
PPARg protein with either SUMO1 or PPARg antibodies (Fig-
ures 4F and S3E). Sumoylation at K107 inhibits PPARg activity
(Floyd and Stephens, 2004; Ohshima et al., 2004; Yamashita
et al., 2004). Thus, these data suggest that in the absence of
FGF21, PPARg transcriptional activity is impaired by sumoyla-
tion at K107.
We investigated whether introduction of the PPARg-K107R
sumoylation mutant into FGF21-KO preadipocytes would
reverse their impaired differentiation phenotype. PPARg-
K395R was also included in these experiments as a control.
Preadipocytes derived from WT and FGF21-KO mice were
infected with lentiviruses expressing either WT PPARg, the
K107R or K395R sumoylation mutants or a control GFP-
expressing virus. As expected, adipocytes from FGF21-KO
mice infected with control (GFP) lentivirus showed decreased
expression of Slc25a1, Acly, Me1, Acaca, Fasn, Dgat2, and
Pck1 at the end of the differentiation period compared to
adipocytes from WT mice (Figure 4G). Expression of
these genes was rescued in FGF21-KO adipocytes by
PPARg-K107R, but not WT PPARg or PPARg-K395R (Fig-
ure 4G). These data indicate that increased sumoylation of
PPARg in FGF21-KO adipocytes contributes to their altered
phenotype., February 3, 2012 ª2012 Elsevier Inc. 559
Figure 3. FGF21-KO Adipocytes Have Altered Gene Expression and Lipid Accumulation
(A and B) Stromal vascular fraction preadipocytes isolated from P4 WT and FGF21-KO mice were differentiated in vitro over an 8 day period. FGF21-KO
preadipocytes were differentiated in either the presence or absence of recombinant FGF21 (200 ng/ml). (A) Gene expression was measured by qRT-PCR.
(B) Lipid accumulation was measured by oil red O staining. Representative oil red O-stained cells at day 8 of differentiation are shown. a, p < 0.05 versus WT; b,
p < 0.01 versus WT.FGF21-KO Mice Are Refractory to Rosiglitazone
If FGF21 is required for full PPARg activity, then FGF21-KO
mice should be resistant to the actions of TZDs. To test this
prediction, groups of diet-induced obese (DIO) WT and
FGF21-KO mice were treated with rosiglitazone or vehicle for
14 days. As expected, rosiglitazone induced FGF21 mRNA
and protein in WAT of WT mice (Figures 5A and 5B). In contrast,
rosiglitazone treatment decreased hepatic Fgf21 mRNA levels
and had little or no effect on hepatic FGF21 protein levels
(Figures 5C and 5D). Circulating FGF21 concentrations were
decreased by rosiglitazone treatment (Figure 5E). These data
provide further evidence that FGF21 synthesized in WAT acts
in an autocrine or paracrine manner rather than circulating as
a hormone.
As expected, rosiglitazone treatment significantly reduced
plasma glucose and insulin concentrations in WT mice (Fig-
ure 5F). Although plasma insulin and glucose levels trended560 Cell 148, 556–567, February 3, 2012 ª2012 Elsevier Inc.lower in rosiglitazone-treated FGF21-KOmice, these differences
were not statistically significant (Figure 5F). Importantly, rosigli-
tazone treatment improved glucose disposal in glucose and
insulin tolerance tests in WT but not FGF21-KO mice (Figures
5G and 5H). In glucose tolerance tests, rosiglitazone decreased
plasma insulin concentrations in both WT and FGF21-KO mice
(Figure 5I). This result was surprising in the FGF21-KOmice given
the lack of an effect of rosiglitazone treatment on glucose
concentrations. Notably, peak insulin concentrations were
significantly higher in WT mice compared to FGF21-KO mice
(Figure 5I), suggesting that FGF21-KO mice have impaired
insulin secretion. This is consistent with the finding that FGF21
stimulated insulin secretion in isolated rodent islets (Wente
et al., 2006). Plasma nonesterified fatty acid and triglyceride
concentrations and hepatic triglyceride concentrations were
either significantly increased or trended upward in FGF21-KO
mice compared to WT mice (Figures 5J–5L). Rosiglitazone
Figure 4. FGF21-KO Adipocytes Have Reduced PPARg Activity
(A and B) Stromal vascular fraction preadipocytes isolated from P4WT and FGF21-KOmice were differentiated for 8 days in the presence of 0.5 mM rosiglitazone
(R), 0.5 mM rosiglitazone plus 100 ng/ml FGF21 (R+F21), or vehicle (V). (A) Gene expression was measured by qRT-PCR (a, p < 0.05 versusWT; b, p < 0.01 versus
WT). (B) Lipid accumulation was measured by oil red O staining (b, p < 0.01; c, p < 0.005).
(C) Sumoylated and total PPARg protein levels were measured in WT and FGF21-KO adipocytes differentiated for 8 days and treated with vehicle or FGF21
(200 ng/ml) for 4 hr prior to harvest. Sumoylated PPARg was detected by immunoprecipitation with a SUMO1 antibody followed by western blot analysis with
a PPARg antibody. Phosphorylated and total PPARg and b-actin were detected by western blot. Top panel shows quantification by densitometry of sumoylated
PPARg normalized to total PPARg for an experiment performed in triplicate (a, p < 0.05). Bottom panel illustrates representative western blots.
(D) Sumoylated and total PPARg protein levels were measured as in (C) in epididymal WAT extracts from 2- to 3-month-old male WT and FGF21-KO mice
fed regular chow and killed in the fed state. Top panel shows quantification by densitometry of sumoylated PPARg normalized to total PPARg forWT and KOmice
(n = 4/group) (a, p < 0.05). Bottom panel illustrates western blots for pooled samples.
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decreased these parameters in FGF21-KO mice to levels
comparable to those in rosiglitazone-treated WT mice. We
conclude that FGF21 is required for some but not all of the meta-
bolic effects of rosiglitazone in DIO mice. We further conclude
that some of these effects are likely to involve FGF21 acting on
tissues other than WAT, including pancreas.
Two well-established side effects of TZDs are increased
adiposity and fluid retention. Although rosiglitazone did not
significantly change body mass in DIO WT or FGF21-KO mice,
it significantly increased fat mass and fluid mass and decreased
leanmass inWTmice (Figures 5M–5P). Notably, the effects of ro-
siglitazone on fat mass, leanmass, and fluidmasswere absent in
FGF21-KO mice (Figures 5N–5P). Thus, FGF21 is required for
both beneficial and adverse effects of rosiglitazone.
We next compared WAT from DIO WT and FGF21-KO mice
treated with rosiglitazone or vehicle. Phosphorylation of Akt at
S473 in WAT was higher in WT mice than FGF21-KO mice after
treatment with either rosiglitazone or rosiglitazone plus insulin
(Figure S4), indicating that the absence of FGF21 impairs insulin
sensitivity in adipose. As expected, rosiglitazone treatment
decreased adipocyte size in WT mice (Figure 6A). Interestingly,
under DIO conditions, adipocytes were larger in FGF21-KO
mice. Furthermore, in DIO FGF21-KO mice, rosiglitazone treat-
ment was less effective at decreasing adipocyte size, and
consequently, the adipocytes remained significantly larger than
those from WT mice treated with rosiglitazone (Figure 6A). As
was observed in chow-fed mice, sumoylated PPARg levels in
WAT were markedly increased in DIO FGF21-KO mice
compared to WT mice (Figure 6B). Consistent with these find-
ings, microarray analysis revealed large clusters of genes that
were either upregulated or downregulated in response to rosigli-
tazone treatment in WT mice, but not in FGF21-KO mice (Fig-
ure 6C). Loss of rosiglitazone responsiveness in FGF21-KO
WAT was confirmed for a subset of PPARg target genes by
qRT-PCR (Figure 6D). For reasons that are not known, basal
expression of Slc25a1 and Fasn was elevated in WAT of
FGF21-KO mice (Figure 6D). Pck1 expression was significantly
reduced in FGF21-KO WAT and unresponsive to rosiglitazone
treatment (Figure 6D). Analysis of adipokines revealed the ex-
pected decrease in Tnfa expression in WAT of WT mice treated
with rosiglitazone (Figure 6E). This response was absent in
FGF21-KO mice (Figure 6E). Although plasma adiponectin
levels increased in response to rosiglitazone administration in
both WT and FGF21-KO mice, this induction was significantly
attenuated in FGF21-KOmice (Figure 6F). Taken together, these
data show that the actions of rosiglitazone are compromised in
DIO FGF21-KO mice.(E) Gene expression was measured by qRT-PCR in the epididymal WAT of 2
(n = 6–7/group) (a, p < 0.05 versus WT; b, p < 0.01 versus WT).
(F) Flag-tagged PPARg2, PPARg2-K107R, PPARg2-K395R, or PPARg2-K107R
and its sumoylation was measured by immunoprecipitation with a Flag antibody
Input levels of Flag-tagged PPARg and the PPARgmutants were determined by w
(a, p < 0.05 versus WT).
(G) Gene expression was measured by qRT-PCR in WT and FGF21-KO strom
PPARg2, PPARg2-K107R, PPARg2-K395R, or GFP control and differentiated fo
comparable levels (Figure S3E). Data are plotted as relative mRNA expression in F
p < 0.01 versus GFP).
Error bars represent the mean ± SEM. See also Figure S3.
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In this report we demonstrate an important role for FGF21 in
regulating PPARg activity in WAT. FGF21 was previously shown
to be induced by PPARg agonists in WAT and to cooperate with
rosiglitazone in promoting differentiation and glucose uptake in
3T3-L1 adipocytes in vitro (Moyers et al., 2007; Muise et al.,
2008; Wang et al., 2008; Zhang et al., 2008). We now show
that lean mice lacking FGF21 have decreased PPARg activity
in WAT and corresponding reductions in WAT mass and adipo-
cyte size. We further show that obese, insulin-resistant mice
lacking FGF21 are refractory to the actions of rosiglitazone,
including both beneficial and adverse effects. We conclude
that the actions of FGF21 and PPARg are fundamentally inter-
twined in WAT.
A surprising result from our studies is that rosiglitazone-
mediated induction of FGF21 in WAT does not cause a corre-
sponding increase in circulating FGF21 in either lean or DIO
mice. In DIO mice, plasma FGF21 levels decreased in parallel
with reduced Fgf21 mRNA in liver. In agreement with a previous
study (Zhang et al., 2008), we show that rosiglitazone treatment
of isolated adipocytes increased FGF21 in the media, demon-
strating that FGF21 is secreted from adipocytes in vitro. A
parsimonious explanation for these data is that FGF21 is
secreted from adipocytes but is unable to reach the circulation,
perhaps due to interactions with the WAT extracellular matrix.
Thus, FGF21 is restricted to acting in an autocrine or paracrine
manner in WAT, much like conventional FGFs. FGF21 is also
proposed to act through an autocrine mechanism in exocrine
pancreas and liver (Fisher et al., 2010; Johnson et al., 2009). In
recent human studies, rosiglitazone treatment had no effect on
circulating FGF21 concentrations in subjects who were either
healthy or had impaired glucose tolerance (Christodoulides
et al., 2009; Mai et al., 2009), but significantly decreased circu-
lating FGF21 in patients with type 2 diabetes (Li et al., 2009a).
This latter study together with the finding that rosiglitazone
induces FGF21 expression in primary cultures of human adipo-
cytes (Zhang et al., 2008) suggest that FGF21 is regulated simi-
larly in mice and man. However, whereas one group reported
that FGF21 mRNA is present in human WAT (Zhang et al.,
2008), another group detected little or no FGF21mRNA in human
WAT samples (Dushay et al., 2010). Additional studies will be
required to determine the relevance of FGF21 expression in
human WAT in both physiologic and pharmacologic contexts.
Previous studies showed that sumoylation of PPARg at K107
represses its transcriptional activity in vitro (Floyd and Stephens,
2004; Ohshima et al., 2004; Yamashita et al., 2004). However, the- to 3-month-old male WT and FGF21-KO mice killed during the fed state
/K395R was introduced into primary FGF21-KO adipocytes by transfection,
followed by western blot analysis with either a SUMO1 or PPARg antibody.
estern blot analysis with a Flag antibody. Data were quantified by densitometry
al vascular fraction preadipocytes transduced with lentiviruses expressing
r 4 days. PPARg2, PPARg2-K107R, and PPARg2-K395R were expressed at
GF21-KO adipocytes compared to WT adipocytes (a, p < 0.05 versus GFP; b,
Figure 5. FGF21-KO Mice Are Refractory to Rosiglitazone Treatment
Two- to three-month-old male WT and FGF21-KO mice were fed a high-fat diet for 10 weeks. During the last 2 weeks, groups of mice were administered
rosiglitazone (10 mg/kg) or vehicle (1%methylcellulose). The following parameters were measured: (A) Fgf21mRNA in epididymal WAT by qRT-PCR; (B) FGF21
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in vivo relevance of this PPARg sumoylation event remained
unclear. We now show that the absence of FGF21 causes
a marked increase in sumoylated PPARg in WAT in vivo. This
increase in sumoylated PPARg corresponds to a decrease in
the expression of PPARg target genes. Our in vitro studies with
FGF21-KO adipocytes show that PPARg sumoylation occurs
at K107. We further show that the effect of FGF21 deficiency
on adipocyte differentiation can be overcome by expressing
a PPARg K107 mutant, strongly suggesting that increased
PPARg sumoylation contributes to the FGF21-KO phenotype.
Precisely how sumoylation blocks the transcriptional activity
of PPARg remains unclear, although in vitro studies suggest
that it may involve the recruitment of corepressor proteins
(Yamashita et al., 2004). Notably, sumoylation of PPARg is
reduced by mutating the adjacent phosphorylation site at
S112 (Yamashita et al., 2004), which also increases PPARg
transcriptional activity (Adams et al., 1997; Hu et al., 1996;
Shao et al., 1998). However, we did not see increased PPARg
S112 phosphorylation in FGF21-KOWAT, suggesting that phos-
phorylation and sumoylation are not coupled in this context.
Based on the data in sum, we propose a feed-forward regula-
tory model wherein PPARg induces FGF21 in WAT, which then
acts in an autocrine or paracrinemanner to block PPARg sumoy-
lation (Figure 6G). The net effect is an increase in PPARg activity
in mid- to late-stage preadipocytes and mature adipocytes,
which express both b-Klotho and FGFR1c. We further propose
that FGF21 contributes to the antidiabetic TZD response in
adipose tissue through at least two PPARg-dependent mecha-
nisms: by increasing the number of small, metabolically active
adipocytes, and by raising adiponectin levels in the circulation.
Although DIO FGF21-KO mice were refractory to rosiglitazone
treatment, we note that the drug response was not eliminated.
Rosiglitazone still significantly decreased plasma and hepatic
triglyceride concentrations and decreased plasma insulin
concentrations in glucose tolerance tests in FGF21-KO mice.
Thus, rosiglitazone has FGF21-independent effects.
Our finding that FGF21 is required for rosiglitazone to increase
adiposity and fluid mass is puzzling for two reasons. First,
whereas the adiposity findings are consistent with FGF21
expression and induction by TZDs in WAT, they appear at
odds with pharmacologic studies in which exogenous FGF21
administration causes significant weight loss in obese animals
(Kharitonenkov et al., 2005, 2007). We suggest that this may
reflect the difference between endogenous FGF21 acting in
a paracrine fashion on WAT alone versus exogenous FGF21
acting coordinately on multiple tissues including liver, where
FGF21 stimulates fatty acid oxidation and ketogenesis (Badman
et al., 2007; Inagaki et al., 2007; Potthoff et al., 2009), BAT,
where FGF21 increases thermogenesis (Hondares et al., 2010),protein in epididymal WAT by ELISA; (C) Fgf21mRNA in liver by qRT-PCR; (D) FG
and insulin; (G) plasma glucose concentrations for glucose tolerance tests in mic
fasted for 4 hr; (I) plasma insulin concentrations during the glucose tolerance te
concentrations; (L) hepatic triglyceride concentrations; (M) body mass; (N) fat ma
For (A)–(E), n = 5–6/group; for (F)–(I), n = 13–16/group; for (J)–(P), n = 5–6/group. Fo
p < 0.05; b, p < 0.01; c, p < 0.005; for (G) and (H), left panels, a, p < 0.05 versusWT
for (I), a, p < 0.05 versus vehicle; b, p < 0.01 versus vehicle; *p < 0.05 versus FG
p < 0.01 versus WT, vehicle; c, p < 0.05 versus WT, rosiglitazone. Error bars rep
564 Cell 148, 556–567, February 3, 2012 ª2012 Elsevier Inc.and the central nervous system, where FGF21 enhances insulin
sensitivity (Sarruf et al., 2010). Thus, pharmacologic administra-
tion of FGF21 may provide a means of obtaining the beneficial,
insulin-sensitizing effects of PPARg agonists without causing
weight gain. A second puzzle is how the absence of FGF21
influences TZD-mediated increases in fluid mass because
neither FGF21 nor its coreceptor, b-Klotho, appears to be
expressed in the kidney (Fon Tacer et al., 2010), where activation
of PPARg decreases urinary sodium excretion and increases
fluid retention (Guan et al., 2005; Zhang et al., 2005). However,
we note that the effects of TZDs on fluid retention are not entirely
eliminated by removing PPARg in kidney (Zhang et al., 2005),
suggesting that other tissues are involved. To our knowledge,
it remains to be determined how FGF21 impacts TZD-mediated
changes in fluid mass.
Why might a hormone that elicits diverse aspects of the star-
vation response—presumably by acting on multiple tissues—
be selectively induced in WAT in the fed state? One possibility
is that FGF21 regulates pathways in WAT that are important
under both fed and fasted conditions. A notable example of
this is triglyceride synthesis. In the fed state, glucose and fatty
acids are stored as triglyceride in WAT. However, triglyceride
synthesis also plays an important role during fasting, when
75% of fatty acids released by lipolysis are reabsorbed and
re-esterified by WAT and other tissues, including liver (Reshef
et al., 2003). This ‘‘triglyceride/fatty acid cycle’’ is believed to
serve as a mechanism for controlling the delivery of substrates
to tissues, including fatty acids and glycerol to the liver for
ketogenesis and gluconeogenesis, respectively (Reshef et al.,
2003). Our finding that FGF21 regulates genes such as Dgat2
and Pck1 is consistent with the notion that it modulates triglyc-
eride homeostasis in both the fed and fasted states. A role for
FGF21 in controlling the triglyceride/fatty acid cycle may also
explain why FGF21 has alternately been reported to stimulate
(Inagaki et al., 2007) or to repress lipolysis in white adipocytes
(Arner et al., 2008; Li et al., 2009b). Although on the one hand
FGF21 induces lipases such as adipose triglyceride lipase and
hormone-sensitive lipase that are involved in triglyceride hydro-
lysis andmobilization (Coskun et al., 2008; Inagaki et al., 2007), it
also induces genes that are involved in triglyceride synthesis.
Thus, the net effect of FGF21 on fatty acid homeostasis likely
depends on the precise physiologic context. A role for FGF21
in modulating the triglyceride/fatty acid cycle is consistent with
the elevated circulating fatty acid levels that occur in FGF21-
KO mice during fasting (Hotta et al., 2009; Potthoff et al., 2009).
In summary we describe an unexpected role for FGF21 in
white adipocytes. We conclude that FGF21 has two disparate
physiologic functions: as an endocrine hormone secreted by
the liver to coordinate the adaptive response during starvation;F21 protein in liver by ELISA; (E) plasma FGF21 by ELISA; (F) plasma glucose
e fasted for 8 hr; (H) plasma glucose levels for insulin tolerance tests in mice
st; (J) plasma nonesterified fatty acid concentrations; (K) plasma triglyceride
ss; (O) lean mass; and (P) fluid mass.
r (A)–(E), a, p < 0.05 versusWT, vehicle; b, p < 0.01 versusWT, vehicle; for (F), a,
, vehicle; b, p < 0.01 versusWT, vehicle; for (G) and (H), right panels, a, p < 0.05;
F21-KO; for (J)–(L), a, p < 0.05; for (N)–(P) a, p < 0.05 versus WT, vehicle; b,
resent the mean ± SEM. See also Figure S4.
Figure 6. FGF21 Is Required for Rosiglitazone Effects in WAT
(A–E) Two- to three-month-old WT and FGF21-KO mice were fed a high-fat diet for 10 weeks. During the last 2 weeks, groups of mice were administered
rosiglitazone (Rosi; 10 mg/kg) or vehicle (1% methylcellulose). The following parameters were measured in epididymal WAT: (A) adipocyte size was
determined using ImageJ software (n > 250 cells/group) (a, p < 0.05; b, p < 0.01; c, p < 0.001). (B) Sumoylated PPARg was detected in epididymal WAT
extracts by either immunoprecipitation with a SUMO1 antibody followed by western blot analysis with a PPARg antibody or the reverse. Total PPARg and
b-actin were measured by western blot analysis. For each lane, WAT extracts were pooled from four mice. Numbers represent relative levels quantified by
densitometry. (C) Microarray analysis resulted in the identification of 545 genes that were significantly changed in response to rosiglitazone treatment in
epididymal WAT from either wild-type or FGF21-KO mice killed in the fed state. A heat map of the data is shown. R, rosiglitazone. (D) Gene expression was
measured by qRT-PCR (n = 5–6/group) (a, p < 0.05 versus WT, vehicle). (E) Tnfa mRNA was measured by qRT-PCR (n = 5–6/group) (a, p < 0.05 versus WT,
vehicle).
(F) Plasma adiponectin concentrations were measured by ELISA (n = 11–14/group) (c, p < 0.001). Error bars represent the mean ± SEM.
(G) Model of the PPARg-FGF21 regulatory pathway in adipose tissue.and as an autocrine or paracrine factor induced in WAT during
the fed state to regulate adipocyte function.EXPERIMENTAL PROCEDURES
Animal Experiments
FGF21-KO mice were generated as described (Potthoff et al., 2009),
including two generations of heterozygous crosses, and maintained ona mixed C57Bl/6 3 129 genetic background as separate WT (Fgf21+/+) and
homozygous KO (Fgf21/) breeding lines. For pure strain studies, FGF21-
KO mice were backcrossed for six generations onto the C57Bl/6 back-
ground. Mice were maintained on a standard chow diet containing 4% fat
(Harlan Teklad Global Diet; #2916). All experiments were performed with
male mice. DIO mice were fed a high-fat diet containing 60% kcal from fat
(Research Diets; #D12492). Oral glucose tolerance tests were performed
on groups of DIO mice treated with rosiglitazone or vehicle for 1 week.
One week later, after being maintained on the high-fat and rosiglitazoneCell 148, 556–567, February 3, 2012 ª2012 Elsevier Inc. 565
regimen, insulin tolerance tests were performed on these same groups of
mice. All animal experiments were approved by the Institutional Animal
Research Advisory Committee of the University of Texas Southwestern
Medical Center at Dallas.
Body Composition Analysis
Body composition was measured using a Bruker Minispec mq10 NMR.
Primary Adipocyte Differentiation Assays
Primary preadipocytes were isolated from postnatal day (P) 4 WT and
FGF21-KO mice, grown to confluency, and differentiated in media containing
high-glucose DMEM plus 10% FBS, 10 mg/ml insulin, 0.5 mM isobutylmethyl-
xanthine, and 0.25 mM dexamethasone.
Microarray Analysis
RNA prepared from epididymal WAT from DIO WT and FGF21-KO mice
treated with rosiglitazone or vehicle for 14 days was reverse transcribed into
cRNA, biotin-UTP labeled, and hybridized to the Illumina mouseRefseq-8v2
Expression BeadChip.
Statistical Analysis
Statistical analyses were performed usingMicrosoft Excel 2007. Comparisons
of two groups were performed using Student’s t test. p < 0.05 was considered
significant.
SUPPLEMENTAL INFORMATION
Supplemental information includes Extended Experimental Procedures and
four figures and can be found with this article online at doi:10.1016/j.cell.
2011.11.062.
ACKNOWLEDGMENTS
We thank Drs. Regina Goetz and Moosa Mohammadi for recombinant FGF21
protein, Dr. James Richardson for histopathology expertise, and members of
the D.J.M./S.A.K. laboratory for discussion. This research was supported by
the Howard Hughes Medical Institute (to D.J.M.), NIH Grants RL1GM084436
and R56DK089600 (to D.J.M. and S.A.K.), U19DK62434 (to D.J.M.), and
GM007062 (to A.L.B.), the Robert A. Welch Foundation (I-1275 to D.J.M.
and I-1558 to S.A.K.), and the LeonaM. andHarry B. Helmsley Charitable Trust
(to R.T.Y.).
Received: May 25, 2011
Revised: October 11, 2011
Accepted: November 15, 2011
Published: February 2, 2012
REFERENCES
Adams, M., Reginato, M.J., Shao, D., Lazar, M.A., and Chatterjee, V.K. (1997).
Transcriptional activation by peroxisome proliferator-activated receptor
gamma is inhibited by phosphorylation at a consensus mitogen-activated
protein kinase site. J. Biol. Chem. 272, 5128–5132.
Arner, P., Pettersson, A., Mitchell, P.J., Dunbar, J.D., Kharitonenkov, A., and
Ryde´n,M. (2008). FGF21 attenuates lipolysis in human adipocytes—apossible
link to improved insulin sensitivity. FEBS Lett. 582, 1725–1730.
Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., and
Maratos-Flier, E. (2007). Hepatic fibroblast growth factor 21 is regulated by
PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states.
Cell Metab. 5, 426–437.
Badman,M.K., Koester, A., Flier, J.S., Kharitonenkov, A., andMaratos-Flier, E.
(2009). Fibroblast growth factor 21-deficient mice demonstrate impaired
adaptation to ketosis. Endocrinology 150, 4931–4940.
Berglund, E.D., Li, C.Y., Bina, H.A., Lynes, S.E., Michael, M.D., Shanafelt, A.B.,
Kharitonenkov, A., and Wasserman, D.H. (2009). Fibroblast growth factor 21566 Cell 148, 556–567, February 3, 2012 ª2012 Elsevier Inc.controls glycemia via regulation of hepatic glucose flux and insulin sensitivity.
Endocrinology 150, 4084–4093.
Cao, Z., Umek, R.M., andMcKnight, S.L. (1991). Regulated expression of three
C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev. 5,
1538–1552.
Chawla, A., Schwarz, E.J., Dimaculangan, D.D., and Lazar, M.A. (1994). Perox-
isome proliferator-activated receptor (PPAR) gamma: adipose-predominant
expression and induction early in adipocyte differentiation. Endocrinology
135, 798–800.
Choi, J.H., Banks, A.S., Estall, J.L., Kajimura, S., Bostro¨m, P., Laznik, D., Ruas,
J.L., Chalmers, M.J., Kamenecka, T.M., Blu¨her, M., et al. (2010). Anti-diabetic
drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature
466, 451–456.
Christodoulides, C., Dyson, P., Sprecher, D., Tsintzas, K., and Karpe, F. (2009).
Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-
activated receptor agonists but not ketosis in man. J. Clin. Endocrinol. Metab.
94, 3594–3601.
Coskun, T., Bina, H.A., Schneider, M.A., Dunbar, J.D., Hu, C.C., Chen, Y.,
Moller, D.E., and Kharitonenkov, A. (2008). Fibroblast growth factor 21
corrects obesity in mice. Endocrinology 149, 6018–6027.
Dushay, J., Chui, P.C., Gopalakrishnan, G.S., Varela-Rey, M., Crawley, M.,
Fisher, F.M., Badman, M.K., Martinez-Chantar, M.L., and Maratos-Flier, E.
(2010). Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty
liver disease. Gastroenterology 139, 456–463.
Fisher, F.M., Chui, P.C., Antonellis, P.J., Bina, H.A., Kharitonenkov, A., Flier,
J.S., and Maratos-Flier, E. (2010). Obesity is a fibroblast growth factor 21
(FGF21)-resistant state. Diabetes 59, 2781–2789.
Floyd, Z.E., and Stephens, J.M. (2004). Control of peroxisome proliferator-
activated receptor gamma2 stability and activity by SUMOylation. Obes.
Res. 12, 921–928.
Fon Tacer, K., Bookout, A.L., Ding, X., Kurosu, H., John, G.B., Wang, L., Goetz,
R., Mohammadi, M., Kuro-o, M., Mangelsdorf, D.J., and Kliewer, S.A. (2010).
Research resource: comprehensive expression atlas of the fibroblast growth
factor system in adult mouse. Mol. Endocrinol. 24, 2050–2064.
Guan, Y., Hao, C., Cha, D.R., Rao, R., Lu, W., Kohan, D.E., Magnuson, M.A.,
Redha, R., Zhang, Y., and Breyer, M.D. (2005). Thiazolidinediones expand
body fluid volume through PPARgamma stimulation of ENaC-mediated renal
salt absorption. Nat. Med. 11, 861–866.
Hondares, E., Rosell, M., Gonzalez, F.J., Giralt, M., Iglesias, R., and Villarroya,
F. (2010). Hepatic FGF21 expression is induced at birth via PPARalpha in
response to milk intake and contributes to thermogenic activation of neonatal
brown fat. Cell Metab. 11, 206–212.
Hotta, Y., Nakamura, H., Konishi, M., Murata, Y., Takagi, H., Matsumura, S.,
Inoue, K., Fushiki, T., and Itoh, N. (2009). Fibroblast growth factor 21 regulates
lipolysis in white adipose tissue but is not required for ketogenesis and
triglyceride clearance in liver. Endocrinology 150, 4625–4633.
Hu, E., Kim, J.B., Sarraf, P., and Spiegelman, B.M. (1996). Inhibition of adipo-
genesis through MAP kinase-mediated phosphorylation of PPARgamma.
Science 274, 2100–2103.
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li,
Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007). Endocrine regulation of
the fasting response by PPARalpha-mediated induction of fibroblast growth
factor 21. Cell Metab. 5, 415–425.
Inagaki, T., Lin, V.Y., Goetz, R., Mohammadi, M., Mangelsdorf, D.J., and
Kliewer, S.A. (2008). Inhibition of growth hormone signaling by the fasting-
induced hormone FGF21. Cell Metab. 8, 77–83.
Johnson, C.L., Weston, J.Y., Chadi, S.A., Fazio, E.N., Huff, M.W., Kharitonen-
kov, A., Ko¨ester, A., and Pin, C.L. (2009). Fibroblast growth factor 21 reduces
the severity of cerulein-induced pancreatitis in mice. Gastroenterology 137,
1795–1804.
Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R.,
Galbreath, E.J., Sandusky, G.E., Hammond, L.J., Moyers, J.S., Owens, R.A.,
et al. (2005). FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627–
1635.
Kharitonenkov, A., Wroblewski, V.J., Koester, A., Chen, Y.F., Clutinger, C.K.,
Tigno, X.T., Hansen, B.C., Shanafelt, A.B., and Etgen, G.J. (2007). The meta-
bolic state of diabetic monkeys is regulated by fibroblast growth factor-21.
Endocrinology 148, 774–781.
Kurosu, H., Choi, M., Ogawa, Y., Dickson, A.S., Goetz, R., Eliseenkova, A.V.,
Mohammadi, M., Rosenblatt, K.P., Kliewer, S.A., and Kuro-o, M. (2007).
Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF)
receptor isoforms determines metabolic activity of FGF19 and FGF21. J.
Biol. Chem. 282, 26687–26695.
Lefterova, M.I., Zhang, Y., Steger, D.J., Schupp, M., Schug, J., Cristancho, A.,
Feng, D., Zhuo, D., Stoeckert, C.J., Jr., Liu, X.S., and Lazar, M.A. (2008).
PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent
binding on a genome-wide scale. Genes Dev. 22, 2941–2952.
Li, K., Li, L., Yang, M., Zong, H., Liu, H., and Yang, G. (2009a). Effects of
rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients
with type 2 diabetes mellitus. Eur. J. Endocrinol. 161, 391–395.
Li, X., Ge, H., Weiszmann, J., Hecht, R., Li, Y.S., Ve´niant, M.M., Xu, J., Wu, X.,
Lindberg, R., and Li, Y. (2009b). Inhibition of lipolysis may contribute to the
acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice. FEBS
Lett. 583, 3230–3234.
Lunda˚sen, T., Hunt, M.C., Nilsson, L.M., Sanyal, S., Angelin, B., Alexson, S.E.,
and Rudling, M. (2007). PPARalpha is a key regulator of hepatic FGF21.
Biochem. Biophys. Res. Commun. 360, 437–440.
Mai, K., Andres, J., Biedasek, K., Weicht, J., Bobbert, T., Sabath, M., Meinus,
S., Reinecke, F., Mo¨hlig, M., Weickert, M.O., et al. (2009). Free fatty acids link
metabolism and regulation of the insulin-sensitizing fibroblast growth factor-
21. Diabetes 58, 1532–1538.
Moyers, J.S., Shiyanova, T.L., Mehrbod, F., Dunbar, J.D., Noblitt, T.W., Otto,
K.A., Reifel-Miller, A., and Kharitonenkov, A. (2007). Molecular determinants
of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J.
Cell. Physiol. 210, 1–6.
Muise, E.S., Azzolina, B., Kuo, D.W., El-Sherbeini, M., Tan, Y., Yuan, X., Mu, J.,
Thompson, J.R., Berger, J.P., and Wong, K.K. (2008). Adipose fibroblast
growth factor 21 is up-regulated by peroxisome proliferator-activated receptor
gamma and altered metabolic states. Mol. Pharmacol. 74, 403–412.
Ogawa, Y., Kurosu, H., Yamamoto, M., Nandi, A., Rosenblatt, K.P., Goetz, R.,
Eliseenkova, A.V., Mohammadi, M., and Kuro-o, M. (2007). BetaKlotho is
required for metabolic activity of fibroblast growth factor 21. Proc. Natl.
Acad. Sci. USA 104, 7432–7437.
Ohshima, T., Koga, H., and Shimotohno, K. (2004). Transcriptional activity of
peroxisome proliferator-activated receptor gamma is modulated by SUMO-1
modification. J. Biol. Chem. 279, 29551–29557.
Pascual, G., Fong, A.L., Ogawa, S., Gamliel, A., Li, A.C., Perissi, V., Rose, D.W.,
Willson, T.M., Rosenfeld, M.G., and Glass, C.K. (2005). A SUMOylation-
dependent pathway mediates transrepression of inflammatory response
genes by PPAR-gamma. Nature 437, 759–763.
Potthoff, M.J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., Moham-
madi, M., Finck, B.N., Mangelsdorf, D.J., Kliewer, S.A., and Burgess, S.C.
(2009). FGF21 induces PGC-1alpha and regulates carbohydrate and fatty
acid metabolism during the adaptive starvation response. Proc. Natl. Acad.
Sci. USA 106, 10853–10858.
Reshef, L., Olswang, Y., Cassuto, H., Blum, B., Croniger, C.M., Kalhan, S.C.,
Tilghman, S.M., and Hanson, R.W. (2003). Glyceroneogenesis and the triglyc-
eride/fatty acid cycle. J. Biol. Chem. 278, 30413–30416.
Rosen, E.D., Sarraf, P., Troy, A.E., Bradwin, G., Moore, K., Milstone, D.S.,
Spiegelman, B.M., and Mortensen, R.M. (1999). PPAR gamma is required
for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4, 611–617.
Sarruf, D.A., Thaler, J.P., Morton, G.J., German, J., Fischer, J.D., Ogimoto, K.,
and Schwartz, M.W. (2010). Fibroblast growth factor 21 action in the brain
increases energy expenditure and insulin sensitivity in obese rats. Diabetes
59, 1817–1824.Shao, D., Rangwala, S.M., Bailey, S.T., Krakow, S.L., Reginato, M.J., and
Lazar, M.A. (1998). Interdomain communication regulating ligand binding by
PPAR-gamma. Nature 396, 377–380.
Spiegelman, B.M., and Flier, J.S. (2001). Obesity and the regulation of energy
balance. Cell 104, 531–543.
Suzuki, M., Uehara, Y., Motomura-Matsuzaka, K., Oki, J., Koyama, Y., Ki-
mura, M., Asada, M., Komi-Kuramochi, A., Oka, S., and Imamura, T. (2008).
betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through
FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22, 1006–1014.
Tontonoz, P., and Spiegelman, B.M. (2008). Fat and beyond: the diverse
biology of PPARgamma. Annu. Rev. Biochem. 77, 289–312.
Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I., and Spiegelman, B.M.
(1994a). mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Genes Dev. 8, 1224–1234.
Tontonoz, P., Hu, E., and Spiegelman, B.M. (1994b). Stimulation of adipogen-
esis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell
79, 1147–1156.
Wang, H., Qiang, L., and Farmer, S.R. (2008). Identification of a domain within
peroxisome proliferator-activated receptor gamma regulating expression of
a group of genes containing fibroblast growth factor 21 that are selectively
repressed by SIRT1 in adipocytes. Mol. Cell. Biol. 28, 188–200.
Wente, W., Efanov, A.M., Brenner, M., Kharitonenkov, A., Ko¨ster, A.,
Sandusky, G.E., Sewing, S., Treinies, I., Zitzer, H., and Gromada, J. (2006).
Fibroblast growth factor-21 improves pancreatic beta-cell function and
survival by activation of extracellular signal-regulated kinase 1/2 and Akt
signaling pathways. Diabetes 55, 2470–2478.
Willson, T.M., Lambert, M.H., and Kliewer, S.A. (2001). Peroxisome prolifera-
tor-activated receptor gamma and metabolic disease. Annu. Rev. Biochem.
70, 341–367.
Wu, Z., Xie, Y., Bucher, N.L., and Farmer, S.R. (1995). Conditional ectopic
expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma and stimu-
lates adipogenesis. Genes Dev. 9, 2350–2363.
Wu, Z., Bucher, N.L., and Farmer, S.R. (1996). Induction of peroxisome
proliferator-activated receptor gamma during the conversion of 3T3 fibro-
blasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocor-
ticoids. Mol. Cell. Biol. 16, 4128–4136.
Wu, Z., Xie, Y., Morrison, R.F., Bucher, N.L., and Farmer, S.R. (1998).
PPARgamma induces the insulin-dependent glucose transporter GLUT4 in
the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into
adipocytes. J. Clin. Invest. 101, 22–32.
Wu, Z., Rosen, E.D., Brun, R., Hauser, S., Adelmant, G., Troy, A.E., McKeon,
C., Darlington, G.J., and Spiegelman, B.M. (1999). Cross-regulation of
C/EBP alpha and PPAR gamma controls the transcriptional pathway of
adipogenesis and insulin sensitivity. Mol. Cell 3, 151–158.
Xu, J., Lloyd, D.J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht,
S., Hecht, R., Li, Y.S., Lindberg, R.A., et al. (2009). Fibroblast growth factor
21 reverses hepatic steatosis, increases energy expenditure, and improves
insulin sensitivity in diet-induced obese mice. Diabetes 58, 250–259.
Yamashita, D., Yamaguchi, T., Shimizu, M., Nakata, N., Hirose, F., and Osumi,
T. (2004). The transactivating function of peroxisome proliferator-activated
receptor gamma is negatively regulated by SUMO conjugation in the amino-
terminal domain. Genes Cells 9, 1017–1029.
Yeh, W.C., Cao, Z., Classon, M., and McKnight, S.L. (1995). Cascade regula-
tion of terminal adipocyte differentiation by threemembers of the C/EBP family
of leucine zipper proteins. Genes Dev. 9, 168–181.
Zhang, H., Zhang, A., Kohan, D.E., Nelson, R.D., Gonzalez, F.J., and Yang, T.
(2005). Collecting duct-specific deletion of peroxisome proliferator-activated
receptor gamma blocks thiazolidinedione-induced fluid retention. Proc. Natl.
Acad. Sci. USA 102, 9406–9411.
Zhang, X., Yeung, D.C., Karpisek, M., Stejskal, D., Zhou, Z.G., Liu, F., Wong,
R.L., Chow,W.S., Tso, A.W., Lam, K.S., and Xu, A. (2008). Serum FGF21 levels
are increased in obesity and are independently associated with the metabolic
syndrome in humans. Diabetes 57, 1246–1253.Cell 148, 556–567, February 3, 2012 ª2012 Elsevier Inc. 567
